{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:03:50Z","timestamp":1787162630302,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Merck Serono SpA"},{"name":"ARCO (Associazione Ricerche e Cure in Oncologia) Foundation"},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer-Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014584","name":"Ignyta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Serono"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck-Serono"},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer and","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejca.2020.04.045","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T07:02:42Z","timestamp":1592204562000},"page":"78-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8456-9269","authenticated-orcid":false,"given":"Roberto","family":"Moretto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Belfiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Boccaccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-7941","authenticated-orcid":false,"given":"Giovanni","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Maria","family":"Germani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Loupakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7742-9556","authenticated-orcid":false,"given":"Luca","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Urbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6359-1712","authenticated-orcid":false,"given":"Silvia","family":"Brich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Marmorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-469X","authenticated-orcid":false,"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Cillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fontanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"De Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2020.04.045_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc2067","article-title":"The tumour microenvironment as a target for chemoprevention","volume":"7","author":"Albini","year":"2007","journal-title":"Nat Rev Canc"},{"issue":"12","key":"10.1016\/j.ejca.2020.04.045_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"7467","key":"10.1016\/j.ejca.2020.04.045_bib3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ejca.2020.04.045_bib4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.ejca.2020.04.045_bib5","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.18.02258","article-title":"Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB\/SWOG 80405 (alliance)","volume":"37","author":"Lenz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2020.04.045_bib6","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/annonc\/mdy410","article-title":"The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial","volume":"29","author":"Mooi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.045_bib7","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2017.35.15_suppl.3510","article-title":"Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and 1st line efficacy of FOLFIRI plus cetuximab or bevacizumab: analysis of the FIRE-3 (AIO KRK 0306) study","volume":"35","author":"Stintzing","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10135","key":"10.1016\/j.ejca.2020.04.045_bib8","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pages","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejca.2020.04.045_bib9","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdz287","article-title":"Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II\/III colorectal cancer","volume":"30","author":"Dienstmann","year":"2019","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2020.04.045_bib10","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2020.04.045_bib11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2020.04.045_bib12","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2020.04.045_bib13","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.celrep.2016.10.009","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","volume":"17","author":"Giannakis","year":"2016","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.ejca.2020.04.045_bib14","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Canc Res"},{"issue":"16","key":"10.1016\/j.ejca.2020.04.045_bib15","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1158\/1078-0432.CCR-15-2879","article-title":"Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy","volume":"22","author":"Becht","year":"2016","journal-title":"Clin Canc Res"},{"issue":"59","key":"10.1016\/j.ejca.2020.04.045_bib16","doi-asserted-by":"crossref","first-page":"31411","DOI":"10.18632\/oncotarget.25830","article-title":"Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies","volume":"9","author":"Iwai","year":"2018","journal-title":"Oncotarget"},{"issue":"6062","key":"10.1016\/j.ejca.2020.04.045_bib17","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.1208347","article-title":"Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice","volume":"334","author":"Michaud","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejca.2020.04.045_bib18","doi-asserted-by":"crossref","first-page":"1703449","DOI":"10.1080\/2162402X.2019.1703449","article-title":"Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology","volume":"9","author":"Vanmeerbeek","year":"2020","journal-title":"OncoImmunology"},{"issue":"8","key":"10.1016\/j.ejca.2020.04.045_bib19","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2020.04.045_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2017.11.008","article-title":"Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation","volume":"63","author":"Ferris","year":"2018","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.ejca.2020.04.045_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/bs.ircmb.2016.09.007","article-title":"Immunomodulatory activity of VEGF in cancer","volume":"330","author":"Lapeyre-Prost","year":"2017","journal-title":"Int Rev Cell Mol Biol"},{"issue":"6","key":"10.1016\/j.ejca.2020.04.045_bib22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.4078","article-title":"The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death","volume":"22","author":"Pozzi","year":"2016","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ejca.2020.04.045_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"issue":"18","key":"10.1016\/j.ejca.2020.04.045_bib24","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-15-3164","article-title":"Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen","volume":"76","author":"Limagne","year":"2016","journal-title":"Canc Res"},{"issue":"3","key":"10.1016\/j.ejca.2020.04.045_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret\u00a0ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"10.1016\/j.ejca.2020.04.045_bib26","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2020.04.045_bib27","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.04.045_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2018.12.028","article-title":"Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial","volume":"109","author":"Cremolini","year":"2019","journal-title":"Eur J Canc"},{"issue":"4","key":"10.1016\/j.ejca.2020.04.045_bib29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2017.5314","article-title":"Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 clinical trial","volume":"4","author":"Cremolini","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2020.04.045_bib30","first-page":"e191","article-title":"Perioperative triplet chemotherapy and cetuximab in patients with RAS wild type high recurrence risk or borderline resectable colorectal cancer liver metastases","volume":"16","author":"Pietrantonio","year":"2017","journal-title":"Clin Colorectal Canc"},{"issue":"1","key":"10.1016\/j.ejca.2020.04.045_bib31","first-page":"34","article-title":"Perioperative bevacizumab-based triplet chemotherapy in patients with potentially resectable colorectal cancer liver metastases","volume":"18","author":"Pietrantonio","year":"2019","journal-title":"Clin Colorectal Canc"},{"issue":"4","key":"10.1016\/j.ejca.2020.04.045_bib32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.21037\/hbsn.2019.03.06","article-title":"Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients","volume":"8","author":"Donadon","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"10","key":"10.1016\/j.ejca.2020.04.045_bib33","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41416-020-0812-z","article-title":"Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases","volume":"122","author":"Stremitzer","year":"2020","journal-title":"Br J Canc"},{"issue":"3","key":"10.1016\/j.ejca.2020.04.045_bib34","first-page":"165","article-title":"The role of cyclooxygenase-2 in colorectal carcinogenesis","volume":"16","author":"Liu","year":"2017","journal-title":"Clin Colorectal Canc"},{"issue":"45","key":"10.1016\/j.ejca.2020.04.045_bib35","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1038\/onc.2008.273","article-title":"HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance","volume":"27","author":"Campoli","year":"2008","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.ejca.2020.04.045_bib36","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJMp1510079","article-title":"Releasing the brakes on cancer immunotherapy","volume":"373","author":"Ribas","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2020.04.045_bib37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.trsl.2015.06.019","article-title":"Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer","volume":"166","author":"Teng","year":"2015","journal-title":"Transl Res"},{"issue":"17","key":"10.1016\/j.ejca.2020.04.045_bib38","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.ejca.2015.08.014","article-title":"Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983","volume":"51","author":"Tanis","year":"2015","journal-title":"Eur J Canc"},{"issue":"7","key":"10.1016\/j.ejca.2020.04.045_bib39","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41416-018-0015-z","article-title":"Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials","volume":"118","author":"Cremolini","year":"2018","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2020.04.045_bib40","article-title":"Randomized phae II study of FOLFOXIRI plus bevacizumab plus atezolizumab versus FOLFOXIRI plus bevacizumab as fist-line treatment of unresectable metastatic colorectal cancer patients","author":"Cremolini","year":"2018","journal-title":"AtezoTRIBE Stud"},{"key":"10.1016\/j.ejca.2020.04.045_bib41","article-title":"Phase II study of avelumab and cetuximb and modified FOLFOXIRI as initial therapy for RAS and BRAF wild-type unresectable metastatic colorectal cancer patients","author":"Falcone","year":"2019","journal-title":"AVETRIC Stud"},{"key":"10.1016\/j.ejca.2020.04.045_bib42","article-title":"Nivolumab plus FOLFOXIRI\/bevacizumab in first line chemotherapy of advanced colorectal cancer RASm\/BRAFm patients","author":"Pinto","year":"2019","journal-title":"NIVACOR Stud"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:45Z","timestamp":1760732865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":42,"alternative-id":["S0959804920302513"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.045","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}